Reaction mixed over FDA committee rejection of MDMA therapy for PTSD.

A recent decision by the U.S. Food and Drug Administration's (FDA) advisory committee to reject psychedelic treatment and therapy to treat post‐traumatic stress disorder (PTSD), citing that the available evidence of midomafetamine, better known as MDMA, fails to show that the drug is effective, has been met with mixed reaction by a member of the field and an advocacy organization committed to advancing safe and equitable access to psychedelic therapies to improve mental health. [ABSTRACT FROM AUTHOR]